Obesity has become one of the biggest health challenges around the world. It affects hundreds of millions of people and greatly increases the risk of serious diseases, including type 2 diabetes, heart disease, stroke, high blood pressure, fatty liver disease, sleep apnea, and some types of cancer.
Carrying too much body fat can also reduce quality of life by making it harder to move, exercise, and perform everyday activities.
Although healthy eating and regular physical activity remain the foundation of weight management, many people find that long-term weight loss is extremely difficult because the body has powerful systems that defend against losing weight.
In recent years, new weight-loss medicines have attracted worldwide attention. However, many require regular injections, can be expensive, and are not suitable for everyone.
Scientists have therefore continued searching for safe, effective pills that could help treat obesity.
Now, researchers at Johns Hopkins Medicine have uncovered an exciting possibility by studying a drug that was originally developed for completely different diseases.
The research focused on an enzyme called phosphodiesterase 9, or PDE9. Enzymes are proteins that help control chemical reactions inside cells.
PDE9 helps regulate a signaling molecule called cyclic GMP, which influences many important processes throughout the body, including metabolism, blood vessel function, and how fat is stored and used.
The research team had previously discovered in 2015 that PDE9 plays an important role in certain forms of heart disease, particularly those linked with high blood pressure. This finding led them to wonder whether blocking the same enzyme might also improve metabolism and reduce obesity.
To test this idea, the scientists studied a drug known as PF-04447943. The medicine was originally developed by Pfizer as a possible treatment for Alzheimer’s disease. Although it did not become an Alzheimer’s treatment, clinical studies involving more than 100 people found that it was generally well tolerated and did not produce serious safety concerns.
Researchers have also explored PDE9 inhibitors for schizophrenia, sickle cell disease, and heart failure.
In the new study, scientists gave the drug to mice with obesity. The results were striking. Without changing the animals’ diet or exercise levels, the medicine reduced body weight, improved heart function, lowered fat accumulation in the liver, and produced healthier metabolic changes.
The researchers also observed improvements in blood sugar control, cholesterol levels, blood pressure, and the way the body processed fat.
These findings suggest that blocking PDE9 changes how the body handles energy rather than simply reducing appetite. The study also supports the growing understanding that obesity is a complex biological disease.
While eating habits and physical activity remain important, genetics, hormones, metabolism, and other biological pathways also play major roles. This helps explain why losing weight is much harder for some people than for others.
Lead researcher Dr. David Kass and his colleagues believe the findings could eventually lead to a completely new type of oral treatment for obesity.
Based on the effects seen in mice, they estimate that if similar results occurred in humans, a person weighing about 250 pounds could potentially lose around 50 pounds without major lifestyle changes. However, this estimate is only a prediction based on animal studies and has not been demonstrated in people.
The findings are particularly important because obesity rates continue to rise worldwide. In the United States, more than 40% of adults are classified as having obesity, increasing the burden of chronic disease and healthcare costs. A safe, affordable pill that targets metabolism could provide another treatment option alongside lifestyle changes and existing medications.
Even so, experts caution that the research is still at an early stage. Results from mice do not always translate to humans. Carefully designed clinical trials will be needed to determine whether PDE9 inhibitors are both safe and effective for people with obesity, what dose works best, and whether any side effects appear after long-term use.
Although much more research is required, this study offers fresh hope that scientists may be able to develop a new generation of weight-loss medicines by targeting the body’s own metabolic pathways.
If future human studies confirm these promising results, a drug once abandoned for another disease could one day become an important new tool for treating obesity and improving the health of millions of people around the world.
The research was led by scientists at Johns Hopkins Medicine and published in the Journal of Clinical Investigation.
If you care about weight loss, please read studies about orange that could help obesity, and a berry that can prevent cancer, diabetes and obesity.
For more health information, please see recent studies about ginger’s journey in weight management ,and green tea: a cup of weight loss.
Copyright © 2026 Knowridge Science Report. All rights reserved.
